Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis.

Duan CM, Wan TF, Wang Y, Yang QW

Medicine1 Nov 2019Cited by 17 (Europe PMC)

PMID31725627PMCIDPMC6867782DOI10.1097/md.0000000000017860PepBankPUB-31725627

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide was associated with lower risk of MACE than all comparator groups (RR 0.89).
In plain wordsIn adults with type 2 diabetes, liraglutide was linked to fewer major heart events than the comparison groups.
Peptide
Liraglutide
Outcome
DecreaseMACE
Study
n = 14,608
Comparator
Placebo or other comparators
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
0.89 RR
MACE
Source sentences
Summary
We found patients in the liraglutide group had a lower risk of major cardiovascular events (MACE) (RR = 0.89, 95% CI: 0.82-0.96, P = .002)
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we searched the PubMed, Embase, and Web of Knowledge databases up to September 1st, 2017 for randomized trials in which type 2 diabetes patients were assigned to liraglutide and placebo or other comparators groups.
Report a problemFND-3172562701
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide was associated with lower risk of acute myocardial infarction than all comparator groups (RR 0.85).
In plain wordsIn adults with type 2 diabetes, liraglutide was linked to fewer heart attacks than the comparison groups.
Peptide
Liraglutide
Outcome
DecreaseAcute myocardial infarction
Study
n = 14,608
Comparator
Placebo or other comparators
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
0.85 RR
AMI
Source sentences
Summary
acute myocardial infarction (AMI) (RR = 0.85, 95% CI: 0.74-0.99, P = .036)
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we searched the PubMed, Embase, and Web of Knowledge databases up to September 1st, 2017 for randomized trials in which type 2 diabetes patients were assigned to liraglutide and placebo or other comparators groups.
Report a problemFND-3172562702
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide was associated with lower risk of all-cause death than all comparator groups (RR 0.84).
In plain wordsIn adults with type 2 diabetes, liraglutide was linked to fewer deaths from any cause than the comparison groups.
Peptide
Liraglutide
Outcome
DecreaseAll-cause death
Study
n = 14,608
Comparator
Placebo or other comparators
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
0.84 RR
all-cause death
Source sentences
Summary
all-cause death (RR = 0.84, 95% CI: 0.74-0.96, P = .009)
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we searched the PubMed, Embase, and Web of Knowledge databases up to September 1st, 2017 for randomized trials in which type 2 diabetes patients were assigned to liraglutide and placebo or other comparators groups.
Report a problemFND-3172562703
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide was associated with lower risk of cardiovascular death than all comparator groups (RR 0.77).
In plain wordsIn adults with type 2 diabetes, liraglutide was linked to fewer heart-related deaths than the comparison groups.
Peptide
Liraglutide
Outcome
DecreaseCardiovascular death
Study
n = 14,608
Comparator
Placebo or other comparators
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
0.77 RR
cardiovascular death
Source sentences
Summary
cardiovascular death (RR = 0.77, 95% CI: 0.65-0.91, P = .002) than all comparator groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we searched the PubMed, Embase, and Web of Knowledge databases up to September 1st, 2017 for randomized trials in which type 2 diabetes patients were assigned to liraglutide and placebo or other comparators groups.
Report a problemFND-3172562704
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide did not decrease the incidence of stroke (RR 0.86, not significant).
In plain wordsIn adults with type 2 diabetes, liraglutide did not lower the number of strokes.
Peptide
Liraglutide
Outcome
No significant changeStroke
Study
n = 14,608
Comparator
Placebo or other comparators
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
0.86 RR
stroke
Source sentences
Summary
However, liraglutide treatment did not decrease incidence of stroke (RR = 0.86, 95% CI: 0.70-1.04, P = .124).
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we searched the PubMed, Embase, and Web of Knowledge databases up to September 1st, 2017 for randomized trials in which type 2 diabetes patients were assigned to liraglutide and placebo or other comparators groups.
Report a problemFND-3172562705
06HumanSystematic reviewEfficacy outcome
In placebo-controlled trials in adults with type 2 diabetes, liraglutide significantly reduced MACE (RR 0.89).
In plain wordsIn placebo-controlled trials in adults with type 2 diabetes, liraglutide lowered major heart events.
Peptide
Liraglutide
Outcome
DecreaseMACE in placebo-controlled trials
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
0.89 RR
placebo-controlled trials
Source sentences
Summary
a significant reduction of MACE with liraglutide was only observed in placebo-controlled trials (RR = 0.89, 95% CI: 0.83-0.96, P = .004)
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we searched the PubMed, Embase, and Web of Knowledge databases up to September 1st, 2017 for randomized trials in which type 2 diabetes patients were assigned to liraglutide and placebo or other comparators groups.
Report a problemFND-3172562706
07HumanSystematic reviewEfficacy outcome
In trials with comparators other than placebo in adults with type 2 diabetes, liraglutide did not significantly reduce MACE (RR 0.58).
In plain wordsIn trials against other treatments than placebo, liraglutide did not clearly lower major heart events.
Peptide
Liraglutide
Outcome
No significant changeMACE in trials with other comparators
Study
n: not reported in source
Comparator
Other comparators
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
0.58 RR
other comparators
Source sentences
Summary
but not in studies concerning other comparators (RR = 0.58, 95% CI: 0.29-1.16, P = .122).
1 context sentence(design, population, supporting numbers)
Summary · context
In this systematic review and meta-analysis, we searched the PubMed, Embase, and Web of Knowledge databases up to September 1st, 2017 for randomized trials in which type 2 diabetes patients were assigned to liraglutide and placebo or other comparators groups.
Report a problemFND-3172562707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.